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Abstract
Background: Ovarian cancer is a malignant tumor with a poor prognosis. Accumulating evidence demonstrates
that long non-coding RNAs (lncRNAs) are emerging regulators in cancer biology, and can be used as potential
biomarkers for cancer diagnosis, prognosis and targeted therapy. The lncRNA CCAT2 (colon cancer associated
transcript 2) was recently shown to be involved in several cancers; however, its role in ovarian cancer remains
unknown.
Methods: Expression levels of the lncRNA CCAT2 in ovarian cancer tissues, adjacent normal tissues, and cell
lines were assessed by quantitative real-time PCR. Then, the associations of CCAT2 expression levels with
clinicopathological features and prognosis were evaluated. In addition, CCAT2 functions in tumor progression
and invasion were further determined by siRNA-induced CCAT2 silencing in vitro.
Results: Expression levels of the lncRNA CCAT2 in ovarian cancer tissues and cell lines were significantly higher
compared with values obtained for adjacent non-tumor tissues and normal ovarian epithelial cells. Interestingly,
higher CCAT2 expression levels were associated with a shorter overall survival (P = 0.006) and disease-free survival
(P = 0.001) in ovarian cancer patients. In addition, CCAT2 expression was positively correlated with FIGO stage
(P = 0.002), tumor grade (P = 0.006) and distant metastasis (P < 0.001). Moreover, CCAT2 knockdown in ovarian
cancer cells markedly suppressed cell proliferation, migration, and invasion.
Conclusions: The lncRNA CCAT2 is a novel factor involved in ovarian cancer progression, and constitutes
a potential prognostic biomarker and therapeutic target for patients with ovarian cancer.
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Background
Ovarian cancer is the leading cause of death from
gynecological malignancies worldwide. More than
230,000 new cases are diagnosed each year, usually at a
late stage; this results in the death of about 140,000
women [1]. Over the past decade, a relatively limited
improvement of survival rates has been achieved in
ovarian cancer. A 5-year survival rate over 90 % can be
achieved with patients diagnosed and treated at early
stages (I and II). Unfortunately, most ovarian cancer
patients are diagnosed with advanced disease (stages III
and IV), in which 5-year survival is less than 30 % [2].
Therefore, there is an urgent need to identify new
biomarkers and novel therapeutic targets for therapeutic
strategy improvement.
Long non-coding RNAs (lncRNAs) are larger than 200
nucleotides; they constitute an emerging class of key
regulatory RNAs that do not code for proteins, and are
crucial players in numerous biological processes,
including chromatin remodeling, gene regulation, dosage
compensation, RNA maturation (splicing, editing), and
genomic imprinting [3]. Abnormal expression of lncRNAs
was reported in different types of cancers [4–8]. In
addition, recent studies demonstrated that differential
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expression of lncRNAs is associated with diagnostic and
prognostic markers for ovarian [9], lung [10], gastric [11]
and liver [12] cancers. However, the role of lncRNAs in
ovarian cancer has only recently been investigated and
remains largely unknown.
The lncRNA CCAT2 (colon cancer-associated tran-
script 2) transcript maps to the highly conserved
8q24.21 region encompassing rs6983267; CCAT2 plays a
crucial role in promoting tumor metastasis, growth, and
chromosomal instability in colon [13], lung [14], breast
[15], and gastric [16] cancers. In colon cancer, CCAT2-
enhances invasion and metastasis through the MYC-
regulated miRNA-17-5p and miRNA-20a [13]. CCAT2
also appears to be involved in migration and chemoresis-
tance in a SNP-independent fashion in breast cancer
[15]. However, CCAT2 expression in ovarian cancer and
the underlying mechanism remain unknown.
This study assessed CCAT2 expression levels in
ovarian cancer tissues, normal ovarian tissues and cell
lines, by quantitative real-time PCR (qRT-PCR). Then,
correlation analysis was carried out to establish the
associations of CCAT2 expression levels with clinico-
pathological features and prognosis. Finally, CCAT2
effects on ovarian cancer cell proliferation, migration
and invasion were further determined via suppression of
the lncRNA CCAT2 in vitro.
Methods
Patients and samples
A total of 109 ovarian cancer and 45 normal ovarian
tissue samples were obtained from patients undergoing
wedge biopsy of the ovaries or adnexectomy due to
myoma or adenomyosis, in Department of Obstetrics
and Gynecology, the First Affiliated Hospital of Nanchang
University (Nanchang, China), between 2007 and 2009.
No patients had received chemotherapy or radiotherapy
prior to surgery. Ovarian cancer was validated by histo-
logical examination in all cases according to World Health
Organization criteria [17]. Ovarian cancer and normal
ovarian tissue specimens excised surgically from patients
were immediately snap-frozen and stored in liquid nitro-
gen until use. Patient characteristics are summarized in
Table 1, including age, histological subtype, distant metas-
tasis, tumor size, tumor grade, and FIGO stage (2009). In
ovarian cancer, primary cytoreductive surgery followed by
platinum-based chemotherapy usually is the mainstay of
treatment. All the enrolled women with ovarian cancer in
this study received primary cytoreductive surgery followed
by platinum-based chemotherapy as follows: paclitaxel
(135 mg/m2) and cisplatin (75 mg/m2) or paclitaxel
(175 mg/m2) and carboplatin (AUC6), administered every
3 weeks for 6 cycles. Informed consent was obtained from
all patients, and the study was approved by the ethics
committee of the First Affiliated Hospital of Nanchang
University (License No. 2013005).
Cell culture and transfection
Standard ovarian cancer cell lines (SKOV3, IGROV1,
A2780, and OVCAR3) and a normal human ovarian
surface epithelial cell line (HOSE 6.3) were obtained
from the American Type Culture Collection. Ovarian
cancer cell lines were routinely cultured in DMEM
(OVCAR-8 and SKOV-3) or RPMI 1640 (A2780 and
IGROV-1), supplemented with 10 % fetal bovine serum
(FBS; Gibco, Grand Island, NY, USA), 100 U/ml peni-
cillin sodium, and 100 mg/ml streptomycin sulfate.
HOSE 6.3 cells were maintained in MCDB Medium 199
(1:1, v/v) containing 10 % FBS [18]. All cells were
cultured in a humidified atmosphere containing 5 %
CO2 at 37 °C.
SKOV3 cells were transfected with siRNA (50 nM)
targeting CCAT2 (si-CCAT2) or a scrambled negative
control (si-NC) (GenePharma, China) using Lipofecta-
mine 2000 (Invitrogen) according to the manufacturer’s
protocol. The sequence selected for CCAT2 siRNA was
5’-AGGTGTAGCCAGAGTTAAT-3’ [13]. Cells were
cultured for 48 h after transfection, and harvested to
determine transfection efficiency by qRT-PCR.
RNA extraction and qRT-PCR
Total RNA was extracted from ovarian cancer tissue sam-
ples, normal ovarian tissue specimens and cultured cells
using TRIzol reagent (Invitrogen, Carlsbad, CA) following
the manufacturer’s instructions. RNA concentrations and
Table 1 Correlation between CCAT2 expression and
clinicopathological features in ovarian cancer patients
Parameters Group Total lncRNA CCAT2 P-value
High Low
Age (years) < 55 50 24 26 0.702
≥ 55 59 31 28
Histological subtypes Serous 78 40 38 0.918
Endometrioid 8 5 3
Mucinous 7 3 4
Clear cell 9 4 5
Others 7 3 4
FIGO stage I + II 33 9 24 0.002
III + IV 76 46 30
Grade G1 42 14 28 0.006
G2 + G3 67 41 26
Distant metastasis Yes 42 36 6 0.000
No 67 19 48
Tumor size (cm) ≤ 10 62 34 28 0.336
> 10 47 21 26
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purity were measured spectrophotometrically at 260 and
280 nm. RNA was reverse transcribed to cDNA by using
Reverse Transcription Kit (Takara) according to the manu-
facturer’s instructions. Real-time qPCR was performed with
a SYBR RT-PCR kit (Takara) on an ABI 7500 Real-Time
PCR System. GAPDH was used as an internal control. The
following primers were used: GAPDH sense 5’-GCAC
CGTCAAGGCTGAGAAC-3’ and reverse 5’-TGGTGAA
GACGCCAGTG GA-3’; CCAT2 sense 5’-CCCTGGTCAA
ATTGCTTAACCT-3’ and reverse 5’-TTATTCGTCCC
TCTGTTTTATGGAT-3 [13]. Fold-changes of CCAT2
levels were derived by the 2−ΔΔCt method, with GAPDH as
a reference gene. Each test was performed in triplicate.
MTT assay
SKOV3 cell proliferation was evaluated by the MTT
(Sigma) assay according to the manufacturer’s instruc-
tions. SKOV3 cells transfected with either si-CCAT2 or
si-NC for 48 h were reseeded into 96-well plates. Cell
density was adjusted to 5 × 103/well, for a final volume
of 150 μl/well. After 24, 48, 72, and 96 h of incubation,
MTT solution (20 μl/well) was added to the plates. The
cells were further cultured for 4 h at 37 °C. Then, the
medium was discarded, with 150 μl DMSO added for
15 min with shaking. Absorbance was measured at
490 nm on an enzyme-labeled analyzer. Three independ-
ent experiments were performed.
Wound healing assay
Migration ability of cells was measured by a wound heal-
ing assay in vitro. Briefly, 2 × 105 SKOV3 cells were seeded
onto 6-well plates, with either si-CCAT2 or si-NC, and
incubated in appropriate complete culture medium for
16 h in normoxic conditions at 37 °C. The monolayer was
scratched and incubated in fresh medium for 24 h. The
wound width was measured after 24 h. Three different
locations were visualized and photographed under a
phase-contrast inverted microscope (Leica, Solms,
Germany).
Transwell invasion assay
Cell invasion assay was performed using 24-well Trans-
well plates (8-μm pore size, Corning Life Sciences)
coated with 1 mg/ml Matrigel (BD Sciences). SKOV3
cells transfected with either si-CCAT2 or si-NC were
resuspended in serum-free medium at 1 × 105 cells/ml,
respectively. Each cell suspension was seeded in the
upper chamber of the Transwell plate in 200 μl FBS-free
medium; the lower chamber was filled with 500 μl 20 %
FBS in medium. After 48 h of incubation at 37 °C with
5 % CO2, cells on the filter surface were fixed with
methanol, stained with 0.1 % crystal violet, and photo-
graphed under a phase-contrast inverted microscope
(Leica). Cells from at least five random microscopic
fields (×100) were counted.
Statistical analysis
Between-group analysis was carried out by independent
t-test for continuous data; Chi-square test was used for
categorical data. Overall survival (OS) and disease-free
survival (DFS) curves were established by the Kaplan-
Meier method, and analyzed by the log-rank test. A Cox
proportional hazard model was constructed to evaluate
the associations of CCAT2 expression with OS and DFS,
respectively. Two-sided P < 0.05 was considered statisti-
cally significant. All statistical analyses were performed
with the SPSS software version 17.0 (SPSS Inc., Chicago,
IL, USA).
Results
CCAT2 gene expression is elevated in ovarian cancer
tissues and cells
Using qRT-PCR, CCAT2 gene expression was assessed
in 109 ovarian cancer tissue samples, 45 normal ovarian
tissue specimens, and cultured ovarian cancer- or normal
cells. Starkly increased CCAT2 gene expression levels
were found in ovarian cancer tissue samples compared
with normal ovarian tissue specimens (Fig. 1a, P < 0.01).
In addition, CCAT2 was significantly up-regulated in four
ovarian cancer cell lines (SKOV3, IGROV1, A2780, and
OVCAR3) compared with normal human ovarian surface
epithelial HOSE 6.3 cells (Fig. 1b, P < 0.01).
Associations of CCAT2 expression with clinicopathological
features in ovarian cancer patients
To further explore the role of CCAT2 in ovarian cancer,
we next evaluated the associations its gene expression
with several clinicopathological features. The 109 patients
were divided into two groups by the median value of
relative CCAT2 gene expression levels: high (n =55) and
low (n =54) expression groups. As shown in Table 1, high
CCAT2 level was not associated with patient age (P =
0.702), histological subtype (P = 0.918) or tumor size (P =
0.336); however it was significantly positively correlated
with FIGO stage (P = 0.002), tumor grade (P = 0.006) and
distant metastasis (P < 0.001). Taken together, these results
supported the notion that CCAT2 up-regulation may be
associated with tumor progression and development.
High CCAT2 levels are correlated with poor prognosis in
ovarian cancer patients
To further explore the potential clinical value of high
CCAT2 expression, the prognostic power of the lncRNA
CCAT2 was determined for OS and DFS in 109 ovarian
cancer patients, using the Kaplan-Meier method and
log-rank test. Interestingly, high CCAT2 expression was
correlated with shorter OS or DFS (P < 0.05, Fig. 2a and
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2b). Univariate Cox proportional hazards regression
model analysis showed that relative CCAT2 expression
level, distant metastasis, tumor grade, and FIGO stage
were correlated with overall survival rate in ovarian
cancer patients (P < 0.05, Table 2). In addition, multivari-
ate analysis revealed CCAT2 expression level, distant
metastasis, tumor grade, and FIGO stage to be inde-
pendent prognostic indicators for overall survival (P <
0.05, Table 2). These data suggested that the lncRNA
CCAT2 could be a bona fide prognostic marker for
ovarian cancer.
Knockdown of the lncRNA CCAT2 inhibits cell
proliferation, migration and invasion
In order to explore the functional role of CCAT2 in
ovarian cancer tumorigenesis, SKOV3 cells were trans-
fected with si-CCAT2 or si-NC. 48 h after transfection,
qRT-PCR was performed to assess CCAT2 gene expres-
sion. As shown in Fig. 3a, cells transfected with si-CCAT2
had significantly decreased CCAT2 mRNA levels com-
pared with the si-NC group (P < 0.05).
Next, cell viability was assessed by MTT assay. As
shown in Fig. 3b, SKOV3 cell transfection with si-CCAT2
Fig. 1 CCAT2 gene expression levels in ovarian cancer tissues and cells. Gene expression levels of the lncRNA CCAT2 were assessed by qRT-PCR,
with GAPDH as an internal control. a CCAT2 expression levels in ovarian cancer samples were significantly higher than those in adjacent
non-tumor tissues. b Higher expression levels of CCAT2 were detected in 4 ovarian cancer cell lines compared with values obtained for the
normal human ovarian surface epithelial HOSE 6.3 cell line. Data are mean ± SD from triplicate experiments *P < 0.05
Fig. 2 Kaplan-Meier survival curves for cervical cancer patients according to CCAT2 gene expression level. OS and DFS of patients with high vs.
Low CCAT2 expression levels are shown. a OS of ovarian cancer patients with high CCAT2 expression was significantly poorer compared with
rates found in patients with low CCAT2 levels (P < 0.05). b DFS of ovarian cancer patients with high CCAT2 expression was significantly poorer
compared with rates in patients with low CCAT2 (P < 0.05)
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resulted in significantly decreased viability compared with
the si-NC group. Furthermore, the role of the lncRNA
CCAT2 in cell migration and invasion was assessed. In
wound healing assay, the migration ability of SKOV3 cells
transfected with si-CCAT2 was significantly decreased
compared with that of the si-NC group (P < 0.05, Fig. 3c).
In addition, Transwell invasion assay revealed reduced
invasion capacity for SKOV3 cells transfected with si-
CCAT2 in comparison with the si-NC group (P < 0.05,
Fig. 3d). These findings demonstrated that CCAT2
Table 2 Univariate and multivariate analyses of prognostic parameters in ovarian cancer patients by Cox regression analysis
Variable Univariate analysis Multivariate analysis
Risk ratio 95 % CI P-value Risk ratio 95 % CI P-value
Age (years) 1.673 0.647–2.309 0. 614
≥ 55 vs < 55
Histologic grade 1.615 0.855–2.742 0.556
Serous vs (Endometrioid + Mucinous + Clear cell + Others)
Tumor size (cm) 1.017 0.722–2.209 0.658
≤ 10 vs > 10
Tumor grade 3.161 1.719–5.839 0.016 3.015 1.623–6.286 < 0.001
G1 vs G2 + G3
Distant metastasis 3.957 1.892–7.413 <0.001 3.253 1.692–6.741 < 0.001
Yes vs No
FIGO stage 2.419 1.401–5.811 0.005 2.724 1.412–5.509 0.003
I + II vs III + IV
lncRNA CCAT2 3.227 1.638–6.279 0.001 2.938 1.526–5.873 < 0.001
High vs Low
Fig. 3 Knockdown of the lncRNA CCAT2 inhibits proliferation, migration and invasion in SKOV3 cells. a qRT-PCR revealed that CCAT2 was
efficiently knocked down by treatment with si-CCAT2 in SKOV3 cells. b SKOV3 cells transfected with si-CCAT2 displayed significantly lower
proliferation ability compared with those transfected with si-NC. c SKOV3 cells transfected with si-CCAT2 showed markedly lower migration ability
compared with those transfected with si-NC. d SKOV3 cells transfected with si-CCAT2 displayed significantly lower invasion ability compared with
those transfected with si-NC. Data are mean ± SD from triplicate experiments. *P < 0.05
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silencing could inhibit cell proliferation, migration and
invasion in vitro.
Discussion
Ovarian cancer, a gynecological malignancy, has been a
leading cause of death among women for the past
decades. The dismal prognosis of ovarian cancer is due
to few symptoms in early-stage; patients are generally
diagnosed with advanced-stage tumors, which are less
susceptible to existing treatments [19]. Therefore, it is
important to explore the molecular events in ovarian
cancer, which would provide insights for improved
diagnosis and prognosis of this deadly disease, thus
improving clinical strategies and outcomes.
It was previously demonstrated that the majority of
RNA transcripts in mammalian cells do not encode
proteins; indeed, protein-coding genes account for only
2 % of the total genome, whereas much of the human
genome, far more than expected, is transcribed into
noncoding RNAs [20]. Among these, lncRNAs have
been confirmed to be important biological RNAs, regu-
lating gene expression at the transcription, epigenetic, or
translation level [21]. Increasing evidence suggests that
lncRNAs are emerging and important regulators of
several biological processes, playing oncogenic or tumor
suppressor roles in tumorigenesis [22, 23]. The lncRNA
CCAT2 is an imprinted and maternally expressed gene,
which promotes the progression of lung [14] and gastric
[16] cancers. However, CCAT2 expression and prog-
nostic role in ovarian cancer remain unclear.
In the present study, CCAT2 gene expression levels
were significantly higher in ovarian cancer tissue sam-
ples and cell lines. To assess whether CCAT2 expression
can serve as a novel prognostic marker, potential associ-
ations of CCAT2 expression with clinicopathological
factors were examined. Interestingly, patients with high
CCAT2 gene expression levels showed poor prognostic
parameters, including FIGO stage and distant metastasis.
In addition, patients with high CCAT2 expression
levels had a significantly poorer prognosis compared
with the low expression group. As shown above, shorter
overall- and disease-free survival times were observed in
the high CCAT2 expression group compared with values
obtained for the low expression group. Moreover, multi-
variate Cox analysis indicated that high CCAT2 expression
was an independent predictor of ovarian cancer. Taken
together, these findings demonstrated for the first time the
clinical significance of the lncRNA CCAT2 in ovarian
cancer.
Zhang et al [24] demonstrated that the lncRNA CCAT2
is upregulated in esophageal squamous cell carcinoma
(ESCC) tissues, with positive correlations between CCAT2
level and lymph node metastasis, TNM stage, and the
number of positive lymph nodes, respectively. In addition,
previous findings demonstrated that CCAT2 is upregu-
lated in breast tumors; indeed, CCAT2 silencing decreases
cell proliferation and invasion in vitro through the Wnt/β-
catenin signaling pathway [25]. Thus, further experiments
are needed to identify the biological processes regulated
by CCAT2 in ovarian cancer. We next silenced CCAT2 in
SKOV3 cells in vitro. As shown above, knockdown of the
lncRNA CCAT2 inhibited cell proliferation, migration and
invasion, further highlighting the role of CCAT2 in cell
biology and oncogenesis of ovarian cancer cells.
Conclusion
In summary, this is the first report showing that lncRNA
CCAT2 expression is significantly high in ovarian cancer
tissues and cell lines. In addition, higher CCAT2 gene
expression level was associated with poor prognosis in
ovarian cancer patients. Moreover, CCAT2 silencing in
ovarian cancer cells markedly suppressed cell prolifera-
tion, migration, and invasion. Taken together, these
findings suggest a potentially important role for CCAT2,
which could serve as a potential biomarker and thera-
peutic target in ovarian cancer.
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